Covid-19: Epidemiology, Pathogenicity and Global Updates

Singh, Manjinder; Nagpal, Manju; Singh, Varinder; Sharma, Ameya; Dhingra, Gitika Arora; Maman, Paramjot; Puri, Vivek

doi:10.22159/ijap.2020v12i5.38439

Cited by 5 publications

(4 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The active site of the main protease comprised Thr24, Thr26, Phe140, Asn142, Gly143, Cys145, His163, His164, Glu166, His172, Arg188, and Gln189. The His41 and Cys145 residues form the catalytic dyad of the enzyme [ 21 , 22 , 23 , 24 ]. The binding energies were determined within the Cdocker module of Discovery Studio.…”

Section: Resultsmentioning

confidence: 99%

Design, Synthesis, and Biological Evaluation of Novel Coumarin Analogs Targeted against SARS-CoV-2

Sharma,

Singh,

Sharma

et al. 2024

Molecules

Self Cite

View full text Add to dashboard Cite

SARS-CoV, an RNA virus, is contagious and displays a remarkable degree of adaptability, resulting in intricate disease presentations marked by frequent genetic mutations that can ultimately give rise to drug resistance. Targeting its viral replication cycle could be a potential therapeutic option to counter its viral growth in the human body leading to the severe infectious stage. The Mpro of SARS-CoV-2 is a promising target for therapeutic development as it is crucial for viral transcription and replication. The derivatives of β-diketone and coumarin have already been reported for their antiviral potential and, thus, are considered as a potential scaffold in the current study for the computational design of potential analogs for targeting the viral replication of SARS-CoV-2. In our study, we used novel diketone-hinged coumarin derivatives against the SARS-CoV-2 MPro to develop a broad-spectrum antiviral agent targeting SARS-CoV-2. Through an analysis of pharmacokinetics and docking studies, we identified a list of the top 10 compounds that demonstrated effectiveness in inhibiting the SARS-CoV-2 MPro virus. On the basis of the pharmacokinetics and docking analyses, the top 5 novel coumarin analogs were synthesized and characterized. The thermodynamic stability of compounds KS82 and KS94 was confirmed by their molecular dynamics, and the stability of the simulated system indicated their inhibitory nature. Molecules KS82 and KS94 were further evaluated for their anti-viral potential using Vero E6 cells followed by RT-PCR assay against SARS-CoV-2. The test compound KS82 was the most active with the potential to inhibit SARS-CoV-2 replication in Vero E6 cells. These data indicate that KS82 prevents the attack of the virus and emerges as the primary candidate with promising antiviral properties.

show abstract

Section: Resultsmentioning

confidence: 99%

Design, Synthesis, and Biological Evaluation of Novel Coumarin Analogs Targeted against SARS-CoV-2

Sharma,

Singh,

Sharma

et al. 2024

Molecules

Self Cite

View full text Add to dashboard Cite

show abstract

“…Coronavirus can be stated as the 'virus in learning', as scientists all over the world are striving hard to study various strains of the virus for the development of an effective therapeutic regimen for the ongoing virus. From studying the new coronavirus variant, the experts said that the new variant "transmits more easily than other strains [5][6][7] .…”

Section: Fig 2: Bar Graph Showing Covid-19 Statistics In Some Of the Countries As Of 28 July 2021mentioning

confidence: 99%

Untitled

Swapna¹,

Reddy²

2021

IJPSR

View full text Add to dashboard Cite

“…SARS-CoV-2 is a type of respiratory virus that can cause pneumonia in sufferers, and the first cases appeared in the city of Wuhan, China since December 2019. The World Health Organization (WHO) recently reported the virus had infected 194 million people and caused 4.16 million deaths [6][7][8]. The high incidence, worsening of disease, increasing death rate and the severe impacts caused by the disease have shown few signs of decreasing in most areas of the world.…”

Section: Introductionmentioning

confidence: 99%

Lessons and New Perspectives: Is Convalescent Plasma Therapy Effective on Covid-19 Patients?

et al. 2022

View full text Add to dashboard Cite

Objective: Recently, convalescent plasma (CP) therapy has shown promising evidence in the treatment of several serious contagious diseases, including SARS-CoV, Influenza and Ebola. We conducted a systematic review to extract data about using CP treatment for COVID-19 patients and it’s effectively. Methods: The retrieval of studies was conducted according to Cochrane Collaboration and from electronic databases including PubMed, Medline, and others (medRxiv and BioRxiv). Searching of the available evidence concerning CP treatment of COVID-19 patients was conducted in journal articles published between December 2019 and October 2020. The articles were further screened based on inclusion and exclusion criteria to identify the high-quality studies for analysis. Results: A total of 18 CP studies were included in this review. We found variance regarding the effectiveness of CP in the reduction of mortality rate, length of stay, and increased discharging rate. Several findings show CP therapy is effective in increasing viral negativity, neutralizing antibodies to recipients, does not cause harmful adverse reactions and in some cases can improve clinical symptoms. This therapy is presently considered effective for generating good clinical outcomes when given early in the course of the disease. Conclusion: The effectiveness of CP in terms of mortality, length of stay, and increased discharging patients is still debatable. However, CP therapy is effective in increasing the negativity of SARS-CoV-2 test, neutralizing antibody titer and is safe so it can be considered for COVID-19 patients. CP should not be given in the initial disease course but is recommended for the early disease course.

show abstract

Covid-19: Epidemiology, Pathogenicity and Global Updates

Cited by 5 publications

References 66 publications

Design, Synthesis, and Biological Evaluation of Novel Coumarin Analogs Targeted against SARS-CoV-2

Design, Synthesis, and Biological Evaluation of Novel Coumarin Analogs Targeted against SARS-CoV-2

Untitled

Lessons and New Perspectives: Is Convalescent Plasma Therapy Effective on Covid-19 Patients?

Contact Info

Product

Resources

About